Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CG Oncology, Inc. Common stock (CGON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: CGON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.91% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.31B USD | Price to earnings Ratio - | 1Y Target Price 68 |
Price to earnings Ratio - | 1Y Target Price 68 | ||
Volume (30-day avg) 956633 | Beta - | 52 Weeks Range 15.71 - 46.99 | Updated Date 04/6/2025 |
52 Weeks Range 15.71 - 46.99 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
Earnings Date
Report Date 2025-03-28 | When - | Estimate -0.46 | Actual -0.48 |
Profitability
Profit Margin - | Operating Margin (TTM) -8344.08% |
Management Effectiveness
Return on Assets (TTM) -15.02% | Return on Equity (TTM) -19.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 571456411 | Price to Sales(TTM) 1150.95 |
Enterprise Value 571456411 | Price to Sales(TTM) 1150.95 | ||
Enterprise Value to Revenue 501.72 | Enterprise Value to EBITDA - | Shares Outstanding 76216896 | Shares Floating 60853824 |
Shares Outstanding 76216896 | Shares Floating 60853824 | ||
Percent Insiders 6.16 | Percent Institutions 98.32 |
Analyst Ratings
Rating 4.62 | Target Price 68.86 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CG Oncology, Inc. Common stock
Company Overview
History and Background
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing oncolytic immunotherapies for patients with bladder cancer. It was founded to address unmet needs in the treatment of this disease.
Core Business Areas
- Oncolytic Immunotherapy Development: Focus on developing novel oncolytic immunotherapy candidates, primarily for bladder cancer.
- Clinical Trials and Regulatory Approvals: Conducting clinical trials to obtain regulatory approval for their lead candidate, cretostimogene grenadenorepvec.
Leadership and Structure
Arthur Kuan is the CEO. The organizational structure is typical of a clinical-stage biotech, focused on R&D, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Cretostimogene Grenadenorepvec (CG0070): An investigational oncolytic immunotherapy being evaluated for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). It's designed to selectively replicate in tumor cells and stimulate an immune response. Market share is currently 0% as it is not yet approved. Competitors include approved therapies such as Keytruda and potential future therapies.
Market Dynamics
Industry Overview
The bladder cancer treatment market is large and growing, with a significant unmet need for effective therapies, especially for patients who have failed BCG therapy. The industry is characterized by innovation in immunotherapy and targeted therapies.
Positioning
CG Oncology is positioned as an innovator in the oncolytic immunotherapy space for bladder cancer, targeting a specific niche of BCG-unresponsive NMIBC. Its competitive advantage lies in its unique mechanism of action and promising clinical data.
Total Addressable Market (TAM)
The TAM for bladder cancer therapies is estimated to be billions of dollars annually. CG Oncology is targeting a significant portion of this market by focusing on BCG-unresponsive NMIBC patients, representing a substantial market opportunity. The expected total market value for bladder cancer therapeutics is projected to reach over $4.7 billion by 2029.
Upturn SWOT Analysis
Strengths
- Novel oncolytic immunotherapy approach
- Promising clinical trial data
- Focus on a specific unmet medical need
- Experienced management team
Weaknesses
- Single product pipeline
- Clinical development risks
- Reliance on regulatory approvals
- Lack of commercial infrastructure
Opportunities
- Potential for accelerated regulatory pathways
- Expansion into other cancer indications
- Partnerships with larger pharmaceutical companies
- Increasing awareness of oncolytic immunotherapy
Threats
- Competition from established therapies
- Unfavorable clinical trial results
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
Competitive Landscape
CG Oncology competes with established pharmaceutical companies offering standard treatments for bladder cancer, as well as other companies developing novel therapies. Its advantage lies in potentially offering a more targeted and effective treatment option for BCG-unresponsive NMIBC.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been characterized by progress in clinical trials and securing financing.
Future Projections: Future growth is dependent on successful completion of clinical trials and potential commercialization of cretostimogene grenadenorepvec. Analyst estimates would vary depending on these factors.
Recent Initiatives: Recent initiatives include advancing the Phase 3 BONDER-006 clinical trial, and presenting clinical trial data.
Summary
CG Oncology is a clinical-stage biopharmaceutical company with a promising oncolytic immunotherapy candidate targeting an unmet need in bladder cancer. The company's success hinges on positive clinical trial results and regulatory approval. While the potential market opportunity is significant, CG Oncology faces competition from established players and clinical development risks. The company needs to successfully commercialize their leading product.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
IMVT
Immunovant Inc
IMVT
Immunovant Inc
NKTR
Nektar Therapeutics
NKTR
Nektar Therapeutics
Sources and Disclaimers
Data Sources:
- CG Oncology Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor. Market share data is based on available sources and estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CG Oncology, Inc. Common stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2024-01-25 | Chairman & CEO Mr. Arthur Kuan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://cgoncology.com |
Full time employees 113 | Website https://cgoncology.com | ||
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.